Taro's generic version of UCB's Keppra oral solution approved by FDA

2/13/2009

ROCKVILLE, Md. The Food and Drug Administration has approved a generic version of UCB's Keppra oral solution, agency records show.

The FDA approved Taro Pharmaceutical Industries' levetiracetam oral solution in the 100-mg-per-milliliter strength. The drug is used to treat epilepsy. 

Keppra had sales of $1.3 billion in 2007, according to UCB financial data. 

X
This ad will auto-close in 10 seconds